Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2026-03-04 @ 3:04 PM
Study NCT ID:
NCT00151450
Status:
COMPLETED
Last Update Posted:
2021-01-22
First Post:
2005-09-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001008', 'term': 'Anxiety Disorders'}], 'ancestors': [{'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069583', 'term': 'Pregabalin'}], 'ancestors': [{'id': 'D005680', 'term': 'gamma-Aminobutyric Acid'}, {'id': 'D000613', 'term': 'Aminobutyrates'}, {'id': 'D002087', 'term': 'Butyrates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 390}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2008-03', 'completionDateStruct': {'date': '2006-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-01-20', 'studyFirstSubmitDate': '2005-09-07', 'studyFirstSubmitQcDate': '2005-09-07', 'lastUpdatePostDateStruct': {'date': '2021-01-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2005-09-09', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluation of the efficacy of pregabalin and Venlafaxine XR in the treatment of generalized anxiety disorder.'}]}, 'conditionsModule': {'conditions': ['Anxiety']}, 'referencesModule': {'references': [{'pmid': '21456104', 'type': 'DERIVED', 'citation': 'Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009 Mar;24(2):87-96. doi: 10.1097/yic.0b013e32831d7980.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081012&StudyName=Comparison+of+Pregabalin+versus+Venlafaxine+XR+and+Placebo+in+the+Treatment+of+Generalized+Anxiety+Disorder', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male and female outpatients with diagnosis of generalized anxiety disorder.\n\nExclusion Criteria:\n\n* Any serious or uncontrolled medical condition.\n* Current diagnosis of depression, dysthymia, obsessive-compulsive disorder.'}, 'identificationModule': {'nctId': 'NCT00151450', 'briefTitle': 'Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients', 'orgStudyIdInfo': {'id': 'A0081012'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Pregabalin', 'type': 'DRUG'}, {'name': 'Venlafaxine XR', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'city': 'De Pinte', 'country': 'Belgium', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 50.99339, 'lon': 3.64747}}, {'city': 'Ghent', 'country': 'Belgium', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Waregem', 'country': 'Belgium', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 50.88898, 'lon': 3.42756}}, {'city': 'Kelowna', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 49.88307, 'lon': -119.48568}}, {'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'city': 'Ottawa', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'city': 'Gatineau', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 45.47723, 'lon': -75.70164}}, {'city': 'Saint-Jean-sur-Richelieu', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 45.30713, 'lon': -73.26259}}, {'city': 'Angoulême', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 45.64997, 'lon': 0.15345}}, {'city': 'Arcachon', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 44.66126, 'lon': -1.17255}}, {'city': 'Bully-les-Mines', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 50.4438, 'lon': 2.72703}}, {'city': 'Cherbourg', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 49.63984, 'lon': -1.61636}}, {'city': 'Élancourt', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.78421, 'lon': 1.9552}}, {'city': 'Orvault', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 47.27117, 'lon': -1.62361}}, {'city': 'Rennes', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.11109, 'lon': -1.67431}}, {'city': 'Saint-André-de-Cubzac', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 44.99455, 'lon': -0.44443}}, {'city': 'Savigny-sur-Orge', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.67677, 'lon': 2.34835}}, {'city': 'Strasbourg', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'city': 'Versailles', 'country': 'France', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 48.80359, 'lon': 2.13424}}, {'city': 'Bray', 'state': 'County Wicklow', 'country': 'Ireland', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.20278, 'lon': -6.09833}}, {'city': 'Vicenza', 'state': 'Bassano DEL Grappa', 'country': 'Italy', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 45.54672, 'lon': 11.5475}}, {'city': 'Città di Castello', 'state': 'Perugia', 'country': 'Italy', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.46556, 'lon': 12.2375}}, {'city': 'Catania', 'country': 'Italy', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'city': 'Sassari', 'country': 'Italy', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.72586, 'lon': 8.55552}}, {'city': 'Wildervank', 'state': 'Provincie Groningen', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.08083, 'lon': 6.8625}}, {'city': 'Hoogvliet', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 51.86333, 'lon': 4.3625}}, {'city': 'Huizen', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 52.29917, 'lon': 5.24167}}, {'city': 'Losser', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 52.26083, 'lon': 7.00417}}, {'city': 'Musselkanaal', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 52.9325, 'lon': 7.01528}}, {'city': 'Oude Pekela', 'country': 'Netherlands', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 53.10417, 'lon': 7.00972}}, {'city': 'Vic', 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 41.93012, 'lon': 2.25486}}, {'city': 'Alcalá de Henares', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.48205, 'lon': -3.35996}}, {'city': 'Langreo', 'state': 'Principality of Asturias', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.29568, 'lon': -5.68416}}, {'city': 'Gandia', 'state': 'Valencia', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 38.96667, 'lon': -0.18333}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Salamanca', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 40.42972, 'lon': -3.67975}}, {'city': 'Zamora', 'country': 'Spain', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 41.50633, 'lon': -5.74456}}, {'city': 'Gothenburg', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'city': 'Linköping', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 58.41086, 'lon': 15.62157}}, {'city': 'Lund', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'city': 'Malmo', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 55.60587, 'lon': 13.00073}}, {'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'city': 'Sundsvall', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 62.39129, 'lon': 17.3063}}, {'city': 'Trollhättan', 'country': 'Sweden', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 58.28365, 'lon': 12.28864}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}